A Phase III, Multicenter, randomized, visual,assessor-masked, active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with Ranibizumab in patients with neovascular age-related macular degeneration.
|Effective start/end date||10/31/18 → 12/31/19|
- Genentech Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.